Don't Overlook Jazz (JAZZ) International Revenue Trends While Assessing the StockZacks Investment Research • Monday
Jazz (JAZZ) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 11/03/26
Jazz Pharmaceuticals (JAZZ) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/02/26
Where Will Jazz Pharmaceuticals Be in 5 Years? Oncology Is Becoming Its Growth EngineThe Motley Fool • 10/27/26
Analysts Estimate Jazz Pharmaceuticals (JAZZ) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 10/26/26
Ziihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026PRNewsWire • 10/23/26
Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 2, 2026PRNewsWire • 10/19/26
Jazz Pharmaceuticals: Ziihera And Portfolio Diversification Are Changing The Earnings StorySeeking Alpha • 10/15/26
Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1BMarketBeat • 09/20/26
Jazz Pharmaceuticals plc (JAZZ) Presents at Deutsche Bank 2026 Healthcare Summit TranscriptSeeking Alpha • 09/16/26
Jazz Pharmaceuticals plc (JAZZ) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/15/26
Jazz Pharmaceuticals plc (JAZZ) Presents at Citigroup's Biopharma Back to School Summit 2026 TranscriptSeeking Alpha • 09/10/26